control of proteinuria with increased doses of agalsidase alfa in a patient with fabry disease with atypical genotype–phenotype expression

control of proteinuria with increased doses of agalsidase alfa in a patient with fabry disease with atypical genotype–phenotype expression

;Christos Paliouras;Georgios Aperis;Foteini Lamprianou;Giorgos Ntetskas;Konstantinos Roufas;Polichronis Alivanis
demiryolu mühendisliği 2015 Vol. 35 pp. 578-581
186
paliouras2015nefrologacontrol

Abstract

Fabry disease is a rare X-linked lysosomal storage disorder of glycosphingolipids, caused by the partial or complete deficiency of the lysosomal enzyme alpha-galactosidase A (a-Gal A). The missense mutation pN215S usually causes a milder form of the disease with isolated cardiac involvement. We report a case of a male Fabry patient with the pN215S mutation and a generalized disease. He suffered a relapse in proteinuria which responded to increased doses of the administered recombinant enzyme. Individualization of enzyme replacement therapy must be considered in selected cases characterized by clinical deterioration.

Citation

ID: 176072
Ref Key: paliouras2015nefrologacontrol
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
176072
Unique Identifier:
10.1016/j.nefroe.2015.09.009
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet